Zensar Technologies Ltd (ZENSARTECH) Q1 FY27 Results Analysis: EBITDA Margin Compresses 163 bps, CIS Segment Surges 16.8%

CompoundingAI Research Updated July 29, 2026 2 min read
Neutral

Zensar Technologies Ltd's Q1 FY27 numbers came in mixed, with revenue of Rs. 1,508.30 Cr (+8.90% YoY) and PAT growth of +1.00% YoY. Here's a quick read of what worked, what to watch, and what management said.

Quick Details
Results dateJuly 29, 2026
QuarterQ1 FY 2026-2027
Revenue (Q1)Rs. 1,508.30 Cr (+8.90% YoY)
PAT (Q1)Rs. 183.80 Cr (+1.00% YoY)
EBITDA margin14.65% (-56 bps YoY)
EPS (Q1)Rs. 8.11 (+1.20% YoY)
Market capRs. 12,190.40 Cr
CMPRs. 535.45

Quarter Snapshot

Revenue grew 4% QoQ and met the 'no degrowth' guidance, but EBITDA margin compressed 163 bps QoQ to 14.65% as subcontracting and other costs surged. Subsidiary PAT collapsed to negligible, leaving PAT flat YoY. The CIS segment continues to drive growth at 16.8% YoY, while the mega deal ramp and cost normalisation in H2 are key catalysts.

Key Investment Insights

Key Positives

  • Revenue grew 4.0% QoQ to Rs.1,508.3 Cr, confirming management's 'no degrowth' guidance for Q1.
  • CIS segment revenue grew 16.8% YoY, outpacing the company average and demonstrating structural demand in cloud and security.
  • Unearned revenue nearly tripled QoQ to Rs.68.5 Cr, indicating strong advance collections.
  • Employee cost as % of revenue improved 329 bps QoQ to 61.15%.

Risk Factors

  • PAT was nearly flat YoY (+1.0%) despite 8.9% revenue growth, showing margin pressure.
  • EBITDA margin fell 163 bps QoQ to 14.65% (lower end of the 14-16% band), partly due to cost surges.
  • Subcontracting costs jumped 33.8% QoQ and 32.0% YoY to 16.23% of revenue.
  • Subsidiary PAT contribution collapsed to just Rs.0.3 Cr from Rs.10.2 Cr YoY, driving the earnings lag.
  • DAS segment EBIT margin at 14.86% is the lowest in available quarters, dropping 134 bps QoQ.
Share on X · LinkedIn · WhatsApp

Disclaimer: This results analysis is published for educational and informational purposes only. It is not investment advice, not a recommendation to buy, sell or hold any security.

Powered by CompoundingAI — AI research platform for Indian stocks, every claim cited from primary filings

Login Now